Derived from the blood-building hormone EPO, but modified so it activates your body's built-in repair system without increasing red blood cell production. It protects nerves, shields tissues from damage, and fights inflammation. Studied for nerve damage (small fiber neuropathy) and the inflammatory condition sarcoidosis.
Dosing
2-4 mg subq daily for 28 days. Can be repeated after a break.
Benefit Profile
Published Research
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.
The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.
The time to develop treatments for diabetic neuropathy.
Managing fatigue in sarcoidosis - A systematic review of the evidence.
Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
Erythropoietin-mediated protection in kidney transplantation: nonerythropoietic EPO derivatives improve function without increasing risk of cardiovascular events.